Menu

Blog

Dec 26, 2022

Classifying aging as a disease could speed FDA drug approvals

Posted by in categories: biotech/medical, life extension

The Food and Drug Administration (FDA) considers aging to be a natural process. This makes it difficult to get FDA approval for drugs that seek to slow or reverse the biological process of aging. Instead, drugs intended to target aging must target a disease that often results from the aging process in order to demonstrate efficacy and gain approval.

But there is growing consensus and effort among scientists to convince the FDA that aging itself should be classified as a disease and an appropriate target for drug development.

Comments are closed.